Related Experiment Videos
Liposome-C-erbB2 antisense oligodoxynucleotides in human ovarian cancer cells
1Hospital of Obstetrics and Gynecology, Fu Dan University, Shanghai 200011, China.
Objective:
To explore the effects of liposome-C-erbB2 antisense phosphorothioate oligodeoxynucleotides (S-ODNs) on C-erbB2 proto-oncogene expression and cell proliferation in human ovarian cancer cells.
Methods:
The effects of liposome-C-erbB2 S-ODNs on C-erbB2 protein expression, cell cycle and cell proliferation in human ovarian cancer cells were studied by means of flow cytometry and 3H-thymidine incorporation.
Results:
Liposome-C-erbB2 S-ODNs can specifically reduce C-erbB2 protein expression in human ovarian cancer cells, accompanied by a 30% inhibition of cell proliferation. The effectiveness of liposome-C-erbB2 S-ODNs on the expression of C-erbB2 was about 40 times higher than that of C-erbB2 S-ODNs.
Conclusions:
The data suggest that antisense therapy might be a useful method of gene therapy in ovarian cancer. The effectiveness of C-erbB2 S-ODNs could be greatly increased by adsorption of S-ODNs by liposomes.
Insights
Liposome-C-erbB2 antisense phosphorothioate oligodeoxynucleotides (S-ODNs) effectively inhibit human ovarian cancer cell proliferation by reducing C-erbB2 proto-oncogene expression. Liposomal delivery significantly enhances S-ODN effectiveness for potential gene therapy applications.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- C-erbB2 proto-oncogene overexpression is implicated in human ovarian cancer progression.
- Antisense oligodeoxynucleotides (S-ODNs) offer a targeted approach to inhibit oncogene expression.
Purpose of the Study:
- To evaluate the efficacy of liposome-encapsulated C-erbB2 antisense phosphorothioate oligodeoxynucleotides (S-ODNs) in human ovarian cancer cells.
- To assess the impact on C-erbB2 proto-oncogene expression and cell proliferation.
Main Methods:
- Liposome-C-erbB2 S-ODNs were administered to human ovarian cancer cells.
- C-erbB2 protein expression was analyzed using flow cytometry.
- Cell proliferation was quantified via 3H-thymidine incorporation assays.
Main Results:
- Liposome-C-erbB2 S-ODNs significantly reduced C-erbB2 protein expression.
- A notable 30% inhibition of ovarian cancer cell proliferation was observed.
- Liposomal formulation enhanced C-erbB2 S-ODN effectiveness by approximately 40-fold compared to non-liposomal S-ODNs.
Conclusions:
- Antisense therapy targeting C-erbB2 shows promise for ovarian cancer gene therapy.
- Liposomal delivery substantially improves the therapeutic potential of C-erbB2 S-ODNs.